Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan

Current Medical Research and Opinion

Volumn 25, Issue 12, 2009, Pages 2933-2949

  Locatelli, Francesco ^a   Palmer, Biff F ^b   Kashihara, Naoki ^c   Ecder, Tevfik ^d  

^a A MANZONI HOSPITAL   (Italy)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Kidney disease; RAAS blockade; Renal protection

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; C REACTIVE PROTEIN; CANDESARTAN; CAPTOPRIL; CILNIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; FOSINOPRIL; HYDROCHLOROTHIAZIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRBESARTAN; LISINOPRIL; METOPROLOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINAPRIL; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR; TRICHLORMETHIAZIDE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; ARTERIAL STIFFNESS; ARTERY RESISTANCE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CELL ACTIVATION; CLINICAL STUDY; CLINICAL TRIAL; COUGHING; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM; ENDOTHELIUM CELL; EVENING DOSAGE; GLOMERULONEPHRITIS; HEART MUSCLE BLOOD FLOW; HEMODIALYSIS PATIENT; HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MONOCYTE; MONOTHERAPY; MORNING DOSAGE; NEPHRITIS; OXIDATIVE STRESS; POLYMORPHONUCLEAR CELL; PROTEIN BLOOD LEVEL; PROTEINURIA; PULSE WAVE; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; URINARY EXCRETION; URINE LEVEL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CYTOPROTECTION; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; KIDNEY; KIDNEY FAILURE, CHRONIC; MODELS, BIOLOGICAL; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 72549090348     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903328231     Document Type: Review

References (93)

1. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007;49(2 Suppl. 2):S12-S154 (Pubitemid 46185743)
2. Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418-423 (Pubitemid 41245551)
3. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation 2006;114:2871-2891 (Pubitemid 46018289)
4. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-147 (Pubitemid 38129105)
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572 (Pubitemid 37430158)
6. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169 (Pubitemid 37337595)
7. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97 (Pubitemid 47016250)
8. Sego S. Pathophysiology of diabetic nephropathy. Nephrol Nurs J 2007;34:631-633
9. Nickenig G, Ostergren J, Struijker-Boudier H. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. J Renin Angiotensin Aldosterone Syst 2006;7(Suppl. 1):S1-S7 (Pubitemid 44383496)
10. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007;13(8 Suppl. S-b):S9-S20 (Pubitemid 350130888)
11. Jandeleit-Dahm KA, Tikellis C, Reid CM, et al. Why blockade of the renin- angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23:463-473 (Pubitemid 40684700)
12. Leiter LA, Lewanczuk RZ. Of the renin-angiotensin system and reactive oxygen species: Type 2 diabetes and angiotensin II inhibition. Am J Hypertens 2005;18:121-128
13. McGuire DK, Winterfield JR, Rytlewski JA, et al. Blocking the renin - angiotensin- aldosterone system to prevent diabetes mellitus. Diab Vasc Dis Res 2008;5:59-66
14. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin- angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-2033 (Pubitemid 41773378)
15. Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008;155:791-805 (Pubitemid 351601744)
16. Shoda J, Kanno Y, Suzuki H. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy. Intern Med 2006;45:193-198
17. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. J Am Soc Nephrol 2006;17:S132-S135
18. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73-87
19. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951
20. Strippoli GF, Bonifati C, Craig M, et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; Issue 4. Art. No.: CD006257. DOI: 10.1002/14651858.CD006257
21. Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type- 1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant 2006;21:2507-2512 (Pubitemid 44644524)
22. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002;40:1023-1029 (Pubitemid 35265483)
23. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000;14(Suppl. 1):S73-S86 (Pubitemid 30409970)
24. Dandona P, Kumar V, Aljada A, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496-4501 (Pubitemid 37153762)
25. Willemsen JM, Westerink JW, Dallinga-Thie GM, et al. Angiotensin II type 1 receptor blockade improves hyperglycemia-induced endothelial dysfunction and reduces proinflammatory cytokine release from leukocytes. J Cardiovasc Pharmacol 2007;49:6-12
26. Hirooka Y, Kimura Y, Sagara Y, et al. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens 2008;30:267-276 (Pubitemid 351556172)
27. Klingbeil AU, John S, Schneider MP, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123-128 (Pubitemid 36143430)
28. Li QZ, Deng Q, Li JQ, et al. Valsartan reduces interleukin-1β secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clin Chim Acta 2005;355:131-136 (Pubitemid 40501140)
29. Liu L, Zhao SP, Zhou HN, et al. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:50-55 (Pubitemid 47220446)
30. Manabe S, Okura T, Watanabe S, et al. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J Cardiovasc Pharmacol 2005;46:735-739 (Pubitemid 44378243)
31. Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48:73-79
32. Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005;27:578-587 (Pubitemid 40835968)
33. Rajagopalan S, Zannad F, Radauceanu A, et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007;100:222-226 (Pubitemid 47041985)
34. Ogawa S, Mori T, Nako K, et al. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension 2006;47:699-705 (Pubitemid 43740241)
35. Rajagopalan S, Kariisa M, Dellegrottaglie S, et al. Angiotensin receptor blockade improves vascular compliance in healthy normotensive elderly individuals: results from a randomized double-blind placebo-controlled trial. J Clin Hypertens (Greenwich) 2006;8:783-790
36. Kosch M, Levers A, Lang D, et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant 2008;23:2280-2285 (Pubitemid 351957584)
37. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients. J Hum Hypertens 2006;20:787-794 (Pubitemid 44430678)
38. Savoia C, Touyz RM, Endemann DH, et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 2006;48:271-277 (Pubitemid 44309823)
39. Nomura S, Shouzu A, Omoto S, et al. Effect of valsartan on monocyte/ endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006;117:385-392 (Pubitemid 43197489)
40. Higuchi T, Abletshauser C, Nekolla SG, et al. Effect of the angiotensin receptor blocker Valsartan on coronary microvascular flow reserve in moderately hypertensive patients with stable coronary artery disease. Microcirculation 2007;14:805-812 (Pubitemid 350131388)
41. Yilmaz MI, Saglam M, Sonmez A, et al. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif 2007;25:327-335 (Pubitemid 47450567)
42. Estacio RO, Coll JR, Tran ZV, et al. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006;19:1241-1248 (Pubitemid 44856249)
43. Hollenberg NK, Parving HH, Viberti G, et al. Albuminuria response to very highdose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-1926 (Pubitemid 47356634)
44. Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension 2008;51:1617-1623
45. Katayama K, Nomura S, Ishikawa H, et al. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int 2006;70:151-156 (Pubitemid 44000132)
46. Katayama S, Yagi S, Yamamoto H, et al. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study. Hypertens Res 2007;30:529-533
47. Menne J, Farsang C, Deák L, et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens 2008;26:1860-1867
48. Muirhead N, Feagan BF, Mahon J, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 diabetes mellitus: a placebo-controlled trial. Curr Ther Res 1999;60:650-660 (Pubitemid 30036150)
49. Uzu T, Sawaguchi M, Maegawa H, et al. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007;30:1581-1583
50. Suzuki K, Souda S, Ikarashi T, et al. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 2002;57:179-183 (Pubitemid 34765734)
51. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-678 (Pubitemid 34851925)
52. Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992-999 (Pubitemid 36359280)
53. Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89-95
54. Hermida RC, Calvo C, Ayala DE, et al. Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 2005;46:960-968
55. Watanabe S, Okura T, Kurata M, et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens 2006;28:451-461 (Pubitemid 44034670)
56. Palmer BF. Supratherapeutic doses of angiotensin receptor blockers to decrease proteinuria in patients with chronic kidney disease. Am J Nephrol 2008;28:381-390
57. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878 (Pubitemid 34940826)
58. Bakris GL, Ruilope L, Locatelli F, et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007;72:879-885 (Pubitemid 47462081)
59. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553
60. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009;53:468-470
61. Berns JS. Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD? Am J Kidney Dis 2009;53:192-196
62. Sarafidis PA, Bakris GL. Renin-angiotensin blockade and kidney disease. Lancet 2008;372:511-512
63. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-2446 (Pubitemid 351793017)
64. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006;29:211-216 (Pubitemid 43853266)
65. Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007;3:486-492
66. Rossi GP. Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists? Curr Hypertens Rep 2006;8:262-268
67. Yoneda T, Takeda Y, Usukura M, et al. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. Am J Hypertens 2007;20:1329-1333 (Pubitemid 350151696)
68. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717
69. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-551
70. Hauben M, Reich L, Gerrits CM, et al. Detection of spironolactone- associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Saf 2007;30:1143-1149 (Pubitemid 350172855)
71. Galle J, Schwedhelm E, Pinnetti S, et al. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 2008;23:3174-3183
72. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860 (Pubitemid 34940824)
73. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869 (Pubitemid 34940825)
74. Ishimitsu T, Kameda T, Akashiba A, et al. Effects of valsartan on the progression of chronic renal insufficiency in patients with nondiabetic renal diseases. Hypertens Res 2005;28:865-870 (Pubitemid 43173955)
75. Perico N, Spormann D, Peruzzi E, et al. Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency. Clin Drug Invest 1997;14:252-259 (Pubitemid 27477552)
76. Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63:1094-1103 (Pubitemid 36315589)
77. Segura J, Praga M, Campo C, et al. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. J Renin Angiotensin Aldosterone Syst 2003;4:43-47 (Pubitemid 36443386)
78. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin- II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124 (Pubitemid 36092015)
79. Kunz R, Wolbers M, Glass T, et al. The COOPERATE trial: a letter of concern. Lancet 2008;371:1575-1576
80. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48 (Pubitemid 351688350)
81. Burgess E, Muirhead N, Rene de Cotret P, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009;20:893-900
82. Muirhead N, House A, Hollomby DJ, et al. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy. Transplant Proc 2003;35:2412-2414 (Pubitemid 37378019)
83. Suzuki H, Kanno Y, Sugahara S, et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004;43:1056-1064 (Pubitemid 38691501)
84. Mazzolai L, Burnier M. Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999;21:23-33 (Pubitemid 29355511)
85. Bakris GL, Kuritzky L. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians. Postgrad Med 2009;121:51-60
86. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084-2092 (Pubitemid 30807937)
87. Durmus A, Dogan E, Erkoc R, et al. Effect of valsartan on erythropoietin and hemoglobin levels in stage III-IV chronic kidney disease patients. Int J Clin Pract 2005;59:1001-1004 (Pubitemid 43918330)
88. Robles NR, Angulo E, Grois J, et al. Comparative effects of fosinopril and irbesartan on hematopoiesis in essential hypertensives. Ren Fail 2004;26:399-404 (Pubitemid 39167617)
89. Marathias KP, Agroyannis B, Mavromoustakos T, et al. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004;4:483-486 (Pubitemid 38854835)
90. Haller H, Viberti GC, Mimran A, et al. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24:403-408 (Pubitemid 43348255)
91. U.S. National Institutes of Health. Aliskiren trial in type 2 diabetes using cardiovascular and renal disease endpoints (ALTITUDE). ClinicalTrials.gov, 2008. Available at: http://www.clinicaltrials.gov/ct/show/NCT00549757 [Last accessed 23 April 2009]
92. U.S. National Institutes of Health. Olmesartan medoxomil in diabetes mellitus. ClinicalTrials.gov, 2008. Available at: http://www.clinicaltrials.gov/ ct/show/NCT00185159 [Last accessed 2 October 2008]
93. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991;121:1244-1263